Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patritumab plus cetuximab and platinum therapy in recurrent or metastatic head and neck squamous cell carcinoma
DRKS00009967Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Patritumab arm with Placebo arm (2 arms). Started May 2016; status: recruiting.
02
Drugs
patritumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on DRKS00009967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00009967.